An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
Medicine (Baltimore)
; 102(30): e34486, 2023 Jul 28.
Article
in En
| MEDLINE
| ID: mdl-37505137
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunoconjugates
/
Triple Negative Breast Neoplasms
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Medicine (Baltimore)
Year:
2023
Type:
Article
Affiliation country:
China